



SELF-ASSESSMENT QUESTIONS FOR PHYSICIANS

Select the 1 best answer to each question and circle that letter on the Answer Grid on the Evaluation Form.

1. A retrospective study of carbonic anhydrase IX (CAIX) suggested that CAIX expression may be an important predictor of outcome in patients with RCC receiving:
 - a. Interferon alpha.
 - b. Interleukin-2.
 - c. Sunitinib.
 - d. Sorafenib.

2. Renal cell carcinomas with papillary histology have been found to respond to high-dose IL-2:
 - a. More often than clear-cell tumors.
 - b. Less often than clear-cell tumors.
 - c. Similarly to clear-cell tumors.
 - d. In the majority of patients.

3. The percentage of patients who have sporadic clear-cell RCC and inactivation of the VHL gene is approximately:
 - a. 10%.
 - b. 20%.
 - c. 40%.
 - d. 60%.

4. The total number of pretreatment clinical features identified as prognostic survival factors for patients with mRCC by the MSKCC model for risk stratification is:
 - a. 3.
 - b. 4.
 - c. 5.
 - d. 6.

5. The average survival time in patients with mRCC who are found to be at poor risk by MSKCC criteria is approximately:
 - a. 3 months.
 - b. 5 months.
 - c. 7 months.
 - d. 8 months.

6. The patient population in the randomized phase 2 trial of sorafenib versus interferon in advanced RCC included patients with mRCC who were:
 - a. Previously treated with sunitinib.
 - b. Previously treated with cytokines.
 - c. Not previously treated.
 - d. In the poor-risk category.



SELF-ASSESSMENT QUESTIONS FOR PHYSICIANS (cont'd)

7. In the pivotal phase 3 trial of sunitinib versus interferon in patients with previously untreated mRCC, median progression-free survival times for sunitinib and interferon were:
 - a. 11 months and 5 months, respectively.
 - b. 8 months and 4 months, respectively.
 - c. 11 months and 10 months, respectively.
 - d. 11 months and 3 months, respectively.

8. In the global ARCC phase 3 trial comparing temsirolimus, IFN- α , or combination therapy, most patients were in the:
 - a. Poor-risk category.
 - b. Good-risk category.
 - c. Intermediate-risk category.
 - d. No category predominated.

9. In a study of interferon alone versus bevacizumab plus interferon in advanced mRCC, the progression-free survival times for the interferon alone arm versus the bevacizumab plus interferon arm in RCC were approximately:
 - a. 8 and 11 months, respectively.
 - b. 5 and 10 months, respectively.
 - c. 6 and 12 months, respectively.
 - d. 8 and 9 months, respectively.

10. Which of the following sequencing therapies has been shown to be superior in prospective studies?
 - a. Sorafenib after sunitinib
 - b. Sunitinib after sorafenib
 - c. Temsirolimus after sunitinib
 - d. Prospective studies are not currently available